Wanbury Limited has scheduled a plant visit and management meeting for investors and analysts on June 5, 2026. The event, organized under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, aims to provide stakeholders with insights into the company's operations. The meeting will be conducted physically at the company's facility.

The discussion during the session will cover the company's past financial results and other information already available in the public domain. This initiative allows investors and analysts to gain a direct understanding of the company's manufacturing capabilities and operational progress.

The schedule for the meeting is as follows:

Wanbury noted that the schedule is subject to change due to exigencies. This includes potential adjustments in case of last-minute cancellations or a drop in participation from investors or brokers. The company will proceed with the event as planned unless such circumstances arise.

The disclosure was submitted to BSE Limited and the National Stock Exchange of India Ltd. The company's registered office is located at BSEL Tech Park, B-wing, 10th Floor, Sector-30 A, Vashi Navi Mumbai.

Wanbury Limited has successfully completed the Korea FDA (Ministry of Food and Drug Safety - MFDS) regulatory inspection at its Patalganga manufacturing facility with zero observations, confirming cGMP compliance per international rules. The inspection was conducted from 7th April to 9th April by two inspectors over three days.

Inspection Details and Outcome

The Korea FDA inspection at the Patalganga site concluded without any regulatory issues, marking a significant achievement for the pharmaceutical company's quality assurance and regulatory compliance efforts. The zero observation outcome confirms the facility's adherence to current Good Manufacturing Practices (cGMP) as per international standards.

PIC Membership and Global Recognition

The Ministry of Food and Drug Safety (MFDS) is part of the Pharmaceutical Inspection Co-operation Scheme (PIC), which enhances the international recognition of this regulatory approval. This membership strengthens the global acceptance of the inspection standards and outcomes.

Multi-Site Regulatory Excellence

Wanbury's regulatory success extends across multiple facilities and international authorities. Both API manufacturing sites at Patalganga and Tanuku are USFDA approved and continue to maintain cGMP compliance. The company has achieved a consistent track record of zero observations across different regulatory bodies.

Infrastructure Development

The company is strengthening its infrastructure by adding a new state-of-the-art manufacturing block at its Andhra Pradesh site for new APIs, which is currently under validation and commercialisation. This expansion demonstrates Wanbury's commitment to enhancing its manufacturing capabilities and capacity.